Evidence map›Paper›PMID 40278263›Full record

ReviewMarine drugs2025

Marine Fungal Metabolites as Potential Antidiabetic Agents: A Comprehensive Review of Their Structures and Enzyme Inhibitory Activities.

Zimin Wang, Meirong Zhao, Yunxia Yu, Fandong Kong, Nanxin Lin, Qi Wang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Marine drugs, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. An Alkaloid from MarinePharmaceuticals (Basel, Switzerland) · 2026
    Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Zimin WangDepartment of Pediatric intensive Care Medicine, Hainan Women and Children's Medical Center, Haikou 570100, China.
Meirong ZhaoCollege of Food and Pharmaceutical Engineering, Guangxi Vocational University of Agriculture, Nanning 530006, China.
Yunxia YuKey Laboratory of Chemistry and Engineering of Forest Products, State Ethnic Affairs Commission, Guangxi Key Laboratory of Polysaccharide Materials and Modification, School of of Marine Science and Biotechnology, Guangxi Minzu University, Nanning 530006, China.
Fandong KongKey Laboratory of Chemistry and Engineering of Forest Products, State Ethnic Affairs Commission, Guangxi Key Laboratory of Polysaccharide Materials and Modification, School of of Marine Science and Biotechnology, Guangxi Minzu University, Nanning 530006, China.
Nanxin LinKey Laboratory of Chemistry and Engineering of Forest Products, State Ethnic Affairs Commission, Guangxi Key Laboratory of Polysaccharide Materials and Modification, School of of Marine Science and Biotechnology, Guangxi Minzu University, Nanning 530006, China.
Qi WangDepartment of Pediatric intensive Care Medicine, Hainan Women and Children's Medical Center, Haikou 570100, China.

Funding

2024 Guangxi Master Graduate Innovation Program YCSW2024278Joint Program on Health Science & Technology Innovation of Hainan Province WSJK2024MS171the Natural Science Foundation of China 82360699
6 · The paper itself

Abstract

Diabetes mellitus has emerged as a global public health crisis, with Type 2 diabetes (T2D) constituting over 90% of cases. Current treatments are palliative, primarily focusing on blood glucose modulation. This review systematically evaluates 181 bioactive compounds isolated from 66 marine fungal strains for their inhibitory activities against key diabetes-related enzymes, including α-glucosidase, protein tyrosine phosphatase 1B (PTP1B), dipeptidyl peptidase-4 (DPP-4), glycogen synthase kinase-3β (GSK-3β), and fatty acid-binding protein 4 (FABP4). These compounds, categorized into polyketides, alkaloids, terpenoids, and lignans, exhibit multitarget engagement and nanomolar-to-micromolar potency. The review highlights the potential of marine fungal metabolites as novel antidiabetic agents, emphasizing their structural novelty and diverse mechanisms of action. Future research should focus on overcoming challenges related to yield and extraction, leveraging advanced technologies such as genetic engineering and synthetic biology to enhance drug development.

Indexed as

Aquatic OrganismsDiabetes Mellitus, Type 2Enzyme InhibitorsFungiHypoglycemic AgentsAnimalsHumansProtein Tyrosine Phosphatase, Non-Receptor Type 1Enzyme InhibitorsHypoglycemic AgentsProtein Tyrosine Phosphatase, Non-Receptor Type 1antidiabetic agentsbioactive compoundsdiabetes mellitusdiabetes-related enzymesmarine fungal strainstype 2 diabetes

Identifiers

PMID40278263
PMCPMC12028496

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.